This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
One biotechnology and drugs stock that insiders are buying up is
Aegerion Pharmaceuticals(AEGR - Get Report), which is focused on the development and commercialization of therapeutics to treat lipid disorders. Insiders are buying this stock into some big time strength, since shares are up a whopping 87% in the last six months.
Aegerion Pharmaceuticals has a market cap of $693 million and an enterprise value of $614 million. This stock trades at a reasonable valuation, with a price-to-book of 8.94. Its estimated growth rate for this year is -20.6%, and for next year it's pegged at 15%. This is a cash-rich company, since the total cash position on its balance sheet is $95.46 million and its total debt is just $10.53 million.
A beneficial owner just
bought 475,000 shares, or $12.85 million worth of stock, at $26.64 to $27.66 per share.
From a technical perspective, AEGR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strongly for the last three months, with shares soaring from its low of $13.50 to its recent high of $28.23 a share. During that uptrend, shares of AEGR have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of AEGR within range of triggering a near-term breakout trade.
If you're bullish on AEGR, then I would look for long-biased trades if this stock manages to break out above some near-term overhead resistance at $28.23 a share with high volume. Look for a sustained move or close above $28.23 a share with volume that registers near or above its three-month average action of 567,997 shares. If that breakout hits soon, then AEGR could easily hit $30 to $35 in the near future. Traders can also buy AEGR off weakness to anticipate that breakout, as long as it doesn't drop back below some near-term support at $25.44 a share.